Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAIS Birch-Alder tablets dose-finding study in tree pollen-induced allergic rhinoconjunctivitis
2012-001822-89Phase 2Completed
- Sponsor
- Lofarma S.p.A.
- Start
- Apr 2012
- Countries
- 1
01
Overview
Phase 2 trial of LAIS Birch-Alder tablets in allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Lofarma S.p.A. Primary endpoint: Change in conjunctival provocation test response threshold. Started Apr 2012; status: completed.
02
Drugs
LAIS Birch-Alder tablets
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2012-001822-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001822-89.